Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Tax Provisions (2020 - 2025)

UroGen Pharma (URGN) has disclosed Tax Provisions for 6 consecutive years, with -$275000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions fell 110.38% year-over-year to -$275000.0, compared with a TTM value of $78000.0 through Dec 2025, down 97.25%, and an annual FY2025 reading of $78000.0, down 97.25% over the prior year.
  • Tax Provisions was -$275000.0 for Q4 2025 at UroGen Pharma, up from -$1.1 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $3.9 million in Q4 2023 and bottomed at -$1.1 million in Q3 2025.
  • Average Tax Provisions over 5 years is $557444.4, with a median of $201500.0 recorded in 2021.
  • Peak annual rise in Tax Provisions hit 2571.05% in 2025, while the deepest fall reached 1258.24% in 2025.
  • Year by year, Tax Provisions stood at $1.1 million in 2021, then tumbled by 39.4% to $689000.0 in 2022, then soared by 459.36% to $3.9 million in 2023, then plummeted by 31.27% to $2.6 million in 2024, then tumbled by 110.38% to -$275000.0 in 2025.
  • Business Quant data shows Tax Provisions for URGN at -$275000.0 in Q4 2025, -$1.1 million in Q3 2025, and $1.0 million in Q2 2025.